P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL

• Yan Gao,
• Xue-Ping LI,
• Xiao-Xiao Wang,
• Bing Bai,
• Xuan-Ye Zhang,
• Su-Xia Lin,
• Yan-Xia He,
• LI-Qin Ping,
• Cheng Huang,
• Ji-Bin LI,
• Jia-Ling Zhuang,
• Hui-Qiang Huang

Affiliations

Yan Gao

1 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

Xue-Ping LI

2 Sun Yat-Sen University Cancer Center, Department of hematology, Guangzhou, China

Xiao-Xiao Wang

1 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

Bing Bai

1 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

Xuan-Ye Zhang

1 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

Su-Xia Lin

3 Sun Yat-Sen University Cancer Center, Department of pathology, Guangzhou, China

Yan-Xia He

4 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

LI-Qin Ping

4 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

Cheng Huang

4 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

Ji-Bin LI

5 Sun Yat-Sen University Cancer Center, Department of Clinical Research, Guangzhou, China

Jia-Ling Zhuang

4 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China

Hui-Qiang Huang

1 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China